Latiglutenase

Because Latiglutenase is an investigational drug, a standardized FDA-approved dosage has not been established. However, clinical trials (such as the ALV003-1221 and Celiac Shield studies) have utilized specific dosing regimens to evaluate efficacy and safety.

• Standard Investigational Dose: 300 mg to 900 mg per meal.
• Frequency: Typically taken three times daily, specifically synchronized with the consumption of breakfast, lunch, and dinner.
• Maximum Studied Dose: Doses up to 1,800 mg per day have been evaluated in short-term safety studies without significant dose-limiting toxicities.

Latiglutenase has not been extensively studied in pediatric populations. Its safety and efficacy in children under the age of 18 have not been established. Clinical trials generally focus on adult populations (ages 18-75) before expanding to pediatric cohorts. Parents should never administer investigational enzymes to children unless enrolled in a supervised clinical trial.

Renal Impairment

Because Latiglutenase is not systemically absorbed, dosage adjustments for patients with mild, moderate, or severe renal impairment are generally not expected to be necessary. The enzymes act locally in the gut and are not cleared by the kidneys.

Hepatic Impairment

Similarly, hepatic (liver) function does not affect the metabolism or clearance of Latiglutenase. No specific dosage adjustments have been recommended for patients with liver disease in current clinical protocols.

Elderly Patients

Clinical trials have included patients up to age 75. While no specific age-related dosage adjustments have been identified, elderly patients should be monitored for general GI tolerance, as they may have different gastric acid profiles or slower gastric emptying times.

To ensure maximum enzymatic activity against gluten, Latiglutenase must be taken correctly:

1. 1Timing: The medication must be taken immediately before or during a meal. Taking the enzymes after a meal significantly reduces their effectiveness, as the gluten may have already passed into the small intestine where the enzymes are less active or become degraded.
2. 2Administration: If using the powder form, mix the prescribed amount with approximately 4 to 6 ounces of water or a room-temperature beverage. Do not mix with very hot liquids, as high temperatures can denature (destroy) the enzymes.
3. 3Consistency: For the best results in clinical trials, patients are instructed to take the medication with every major meal, regardless of whether they believe the meal is gluten-free, to protect against hidden gluten.
4. 4Storage: Most enzyme preparations require storage in a cool, dry place. Some formulations may require refrigeration to maintain enzymatic potency. Always check the specific storage instructions provided by the clinical trial site.

If you miss a dose of Latiglutenase and have already finished your meal, do not take the missed dose. The enzymes must be present in the stomach simultaneously with the food to work. Simply wait until your next meal and take the scheduled dose. Do not double the dose to make up for a missed one.

Since Latiglutenase is not absorbed into the bloodstream, a systemic overdose is highly unlikely. However, ingesting very large quantities may lead to localized gastrointestinal distress, including:

• Severe abdominal cramping
• Osmotic diarrhea
• Nausea

In the event of an accidental ingestion of an excessive amount, contact a poison control center or seek medical attention, particularly if you experience severe allergic symptoms.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or stop taking the medication without medical guidance from the clinical trial investigator.

In clinical trials, Latiglutenase has been generally well-tolerated, with a safety profile similar to that of a placebo. However, some patients may experience gastrointestinal symptoms as the body adjusts to the enzyme therapy or due to the underlying Celiac disease. Common reports include:

• Abdominal Bloating: A feeling of fullness or pressure in the upper abdomen, often occurring shortly after mealtime.
• Flatulence (Gas): Increased gas production as the enzymes break down proteins in the stomach.
• Nausea: Mild queasiness, which usually resolves as treatment continues.
• Changes in Bowel Habits: Some patients report mild diarrhea or constipation during the first week of therapy.

These effects are less frequent but have been noted in clinical data:

• Abdominal Pain: Cramping or discomfort in the mid-abdominal region.
• Dyspepsia (Indigestion): A burning sensation or discomfort in the upper digestive tract.
• Headache: Reported by some participants, though a direct causal link to the enzymes is not always clear.
• Fatigue: General feelings of tiredness or low energy.

• Hypersensitivity Reactions: Because the enzymes are derived from barley and bacteria, there is a theoretical risk of an allergic reaction. This may manifest as a mild rash or itching.
• Vomiting: Rare instances of acute gastric upset.

While serious adverse events are rare with Latiglutenase due to its lack of systemic absorption, patients must remain vigilant for signs of a severe reaction.

> Warning: Stop taking Latiglutenase and call your doctor immediately if you experience any of these:

1. 1Anaphylaxis: Signs include difficulty breathing, swelling of the face, lips, or tongue, severe dizziness, or a rapid heartbeat. This is a life-threatening emergency.
2. 2Severe Skin Reactions: Widespread hives, blistering, or peeling skin.
3. 3Intense Abdominal Pain: Pain that is sharp, localized, or worsening, which could indicate a complication unrelated to the medication but requiring urgent evaluation.
4. 4Persistent Vomiting: Inability to keep down fluids or food, leading to dehydration.

Because Latiglutenase is still in the investigational phase, long-term safety data (beyond 1-2 years of use) is limited. Theoretical concerns that are monitored in long-term studies include:

• Nutritional Alterations: Whether the long-term use of exogenous proteases affects the absorption of other essential proteins or vitamins.
• Immunogenicity: The possibility that the body could develop antibodies against the foreign enzymes (EP-B2 or SC PEP). In clinical trials to date, no clinically significant neutralizing antibodies have been identified that interfere with the drug's efficacy or cause systemic harm.
• Microbiome Changes: The impact of altered protein degradation on the balance of gut bacteria (gut microbiota).

As of 2026, there are no FDA black box warnings for Latiglutenase. It is not currently associated with the high-risk safety profiles that require such warnings (e.g., increased risk of death, organ failure, or suicidal ideation).

Report any unusual symptoms or changes in your health to your healthcare provider or clinical trial coordinator immediately. Your feedback is essential for the ongoing safety monitoring of this investigational therapy.

Latiglutenase is designed specifically for individuals with Celiac disease or gluten-related disorders. It is not a general digestive enzyme and should not be used by individuals without a confirmed diagnosis. Most importantly, Latiglutenase does not permit a return to a normal gluten-containing diet. It is intended to be used alongside a strict gluten-free diet to protect against accidental, low-level exposure.

No FDA black box warnings for Latiglutenase. The safety profile observed in Phase 2 and Phase 3 trials suggests the medication is generally safe for the target population when taken as directed.

Allergic Reactions / Anaphylaxis Risk

Since Latiglutenase contains proteins derived from barley (EP-B2) and bacteria (SC PEP), there is a risk of hypersensitivity. Patients with known severe allergies to barley or specific bacterial proteins should exercise extreme caution. If you have a history of anaphylaxis to food products, discuss this with your doctor before starting Latiglutenase.

Gastric pH and Efficacy

Latiglutenase requires an acidic environment in the stomach to function optimally. Conditions or medications that significantly raise gastric pH (making the stomach less acidic) may reduce the effectiveness of the enzymes. This includes the use of high-dose proton pump inhibitors (PPIs) or antacids.

Misuse for 'Gluten Loading'

There is a significant risk that patients may use Latiglutenase as a justification to intentionally consume gluten. Patients must be warned that the enzyme has a finite capacity to degrade gluten; it can be 'overwhelmed' by large amounts of gluten (e.g., a slice of bread or a bowl of pasta), leading to severe intestinal damage despite taking the medication.

Patients taking Latiglutenase in a clinical or post-approval setting may require the following monitoring:

• Serology Tests: Periodic blood tests for Celiac antibodies (e.g., anti-tTG IgA) to ensure the disease is well-managed.
• Symptom Logs: Tracking gastrointestinal symptoms to determine if the medication is providing clinical benefit.
• Biopsy (in trials): In some clinical studies, follow-up intestinal biopsies are performed to assess the health of the villi.

Latiglutenase is not known to cause drowsiness, dizziness, or cognitive impairment. It is generally considered safe to drive or operate heavy machinery while taking this medication.

There is no known direct interaction between Latiglutenase and alcohol. However, alcohol can irritate the lining of the stomach and intestines, which may worsen the symptoms of Celiac disease. Patients are generally advised to limit alcohol consumption to support intestinal healing.

Latiglutenase can be stopped abruptly without the risk of withdrawal symptoms or 'rebound' effects. However, once the medication is stopped, the protective effect against accidental gluten exposure is immediately lost. If you stop taking the medication, you must be even more vigilant about your gluten-free diet.

> Important: Discuss all your medical conditions, especially any history of severe allergies or digestive disorders, with your healthcare provider before starting Latiglutenase.

Currently, there are no medications that are strictly contraindicated for use with Latiglutenase. However, because it is a protein-based enzyme, it should not be taken with other agents that might denature or deactivate the enzymes before they can act on gluten.

Proton Pump Inhibitors (PPIs) and H2 Blockers

• Drugs: Omeprazole, Esomeprazole, Ranitidine, Famotidine.
• Mechanism: These drugs reduce stomach acid. The EP-B2 enzyme in Latiglutenase is most active at a pH of 3.0 to 5.0. If the stomach pH rises above 6.0 due to acid-suppressing medication, the enzymes may not break down gluten efficiently.
• Management: Your doctor may suggest timing your Latiglutenase dose as far apart from your PPI dose as possible, or they may monitor your symptoms more closely.

Other Digestive Enzymes

• Drugs: Pancrelipase, Bromelain, Papain.
• Mechanism: Taking multiple types of enzymes simultaneously could theoretically lead to the enzymes digesting each other (proteolysis of the therapeutic enzymes).
• Management: Avoid taking other supplemental enzymes at the exact same time as Latiglutenase unless directed by a specialist.

Oral Protease Inhibitors

• Drugs: Certain antiviral medications used for HIV or Hepatitis C.
• Mechanism: While these drugs target viral proteases, there is a theoretical possibility of cross-reactivity with the enzymes in Latiglutenase.
• Management: Consult your pharmacist to ensure no specific interactions exist with your antiviral regimen.

High-Temperature Foods

• Interaction: Consuming Latiglutenase with very hot soups or beverages.
• Consequence: Heat can permanently deactivate the enzymes.
• Management: Ensure food and drinks are at a comfortable, 'mouth-safe' temperature before taking the medication.

Carbonated Beverages

• Interaction: Mixing Latiglutenase powder with soda or sparkling water.
• Consequence: The acidity and carbonation may affect the stability of the enzyme mixture.
• Management: Use plain water or non-acidic juices for mixing.

St. John's Wort and Ginkgo Biloba

There are no known interactions between these supplements and Latiglutenase, as Latiglutenase is not absorbed systemically and does not interact with the cytochrome P450 enzyme system in the liver.

Latiglutenase is not known to interfere with standard blood chemistry, hematology, or urinalysis tests. It does not affect the results of Celiac serology tests (anti-tTG), although successful treatment may lead to a decrease in these antibody levels over time as intestinal health improves.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter antacids and digestive aids.

There are few absolute contraindications for Latiglutenase due to its localized action, but the following apply:

1. 1Severe Allergy to Barley: Since the EP-B2 component is derived from barley, individuals with a known anaphylactic allergy to barley should not use this medication. While the enzyme is highly purified, the risk of cross-reactivity is a serious concern.
2. 2Hypersensitivity to any Component: If a patient has previously experienced a severe allergic reaction to Latiglutenase or its excipients (inactive ingredients), they must never take it again.

These conditions require a careful risk-benefit analysis by a healthcare provider:

• Achlorhydria (Lack of Stomach Acid): Patients who do not produce stomach acid may find the medication ineffective, as the enzymes require an acidic environment to activate and degrade gluten.
• Severe Gastroparesis (Delayed Gastric Emptying): If food remains in the stomach for excessively long periods, the enzymes themselves may be degraded by natural gastric juices before they finish breaking down the gluten.
• Active Gastrointestinal Bleeding: The presence of blood in the stomach might interfere with enzyme activity or exacerbate irritation in the area of the bleed.

Patients with allergies to other fungal or bacterial-derived enzymes (such as those found in some laundry detergents or industrial food processing) should be monitored for cross-sensitivity. However, there is no known cross-sensitivity with common medications like penicillin or sulfa drugs.

> Important: Your healthcare provider will evaluate your complete medical history, including any rare allergies or digestive conditions, before prescribing Latiglutenase.

FDA Pregnancy Category

Latiglutenase has not been assigned a formal FDA pregnancy category as it is still investigational.

Risks and Considerations

Because Latiglutenase is not absorbed systemically, the risk of direct fetal exposure is considered extremely low. However, maintaining optimal maternal nutrition is vital in Celiac disease. If accidental gluten exposure causes severe malabsorption in the mother, it could indirectly affect the fetus.

• Trimester Data: There is no specific data regarding use in the first, second, or third trimesters.
• Recommendation: Use during pregnancy should only be considered if the potential benefit justifies the potential risk to the fetus, and only under strict medical supervision.

It is highly unlikely that Latiglutenase passes into breast milk because the enzymes are not absorbed into the mother's bloodstream. They are large proteins that are digested in the mother's GI tract.

• Infant Safety: No adverse effects on nursing infants have been reported in the limited data available.
• Decision Making: Breastfeeding mothers should consult their doctor. The primary concern is ensuring the mother's Celiac disease is well-controlled to maintain the nutritional quality of the breast milk.

As of 2026, Latiglutenase is not approved for use in children. The safety and efficacy in patients under 18 years of age are currently unknown. Clinical trials are necessary to determine the appropriate dosage and to ensure that the enzymes do not interfere with the natural digestive development of children.

Clinical studies have included a limited number of patients over age 65.

• Pharmacokinetics: No significant differences in enzyme activity are expected in the elderly, provided they have adequate gastric acid production.
• Polypharmacy: The main concern in geriatric patients is the use of multiple other medications (e.g., PPIs for acid reflux) that might interfere with Latiglutenase efficacy.
• Fall Risk: There is no evidence that Latiglutenase increases the risk of falls or cognitive impairment in the elderly.

No dosage adjustment is required for patients with renal impairment. The kidneys are not involved in the clearance of this medication.

No dosage adjustment is required for patients with hepatic impairment. The liver does not metabolize Latiglutenase.

> Important: Special populations, particularly pregnant women and the elderly, require individualized medical assessment to ensure that the use of an investigational enzyme is appropriate for their specific health profile.

Latiglutenase is a fixed-dose combination of two proteases: EP-B2 (a glutamine-specific endoprotease) and SC PEP (a proline-specific endopeptidase).

• EP-B2: Originating from the germinating barley seed, this enzyme is a cysteine protease. It preferentially cleaves peptide bonds after glutamine residues. In the stomach, it rapidly breaks down complex gluten proteins into smaller, more manageable peptides.
• SC PEP: Derived from the bacterium Sphingomonas capsulata, this enzyme is a prolyl endopeptidase. It targets the proline-rich sequences that are characteristic of gluten's immunogenic fragments.

Together, they provide a 'one-two punch' that degrades the 33-mer immunodominant peptide into fragments shorter than 9 amino acids, which are too small to be recognized by the T-cells of the immune system.

• Dose-Response: Clinical trials show a dose-dependent reduction in gluten-induced mucosal injury. Higher doses (e.g., 900 mg) generally show more robust degradation of gluten in gastric aspirate studies.
• Time to Onset: The enzymes begin working immediately upon contact with gluten in the stomach.
• Duration of Effect: The effect lasts as long as the enzymes remain active in the stomach, typically 30 to 90 minutes depending on the size and composition of the meal.
• Tolerance: There is no evidence that the body develops tolerance to the enzymes; they remain effective with repeated use.

| Parameter | Value |

|---|---|

| Bioavailability | ~0% (Not systemically absorbed) |

| Protein Binding | N/A (Does not enter circulation) |

| Half-life | N/A (Degraded in the GI tract) |

| Tmax | N/A |

| Metabolism | Digested by pepsin/trypsin into amino acids |

| Excretion | Fecal (as degraded protein) |

• Components: EP-B2 (recombinant) and SC PEP (recombinant).
• Molecular Weight: EP-B2 is approximately 45 kDa; SC PEP is approximately 75 kDa.
• Solubility: Soluble in aqueous solutions; stable in acidic pH (pH 3-5).
• Structure: Complex globular proteins with specific active sites for peptide cleavage.

Latiglutenase is classified as a Non-Standardized Food Allergenic Extract [EPC] and a digestive enzyme. It is the first in a potential new class of 'Gluten-Degrading Oral Enzyme Therapies.'